Article
Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.
Oncotarget - 30 Mar 2015
Martin-Castillo Begoña, Lopez-Bonet Eugeni, Buxó Maria, Dorca Joan, Tuca-Rodríguez Francesc, Ruano Miguel Alonso, Colomer Ramon, Menendez Javier A
Abstract excerpt
There is an urgent need to refine the prognostic taxonomy of HER2+ breast carcinomas and develop easy-to-use, clinic-based prediction algorithms to distinguish between good- and poor- responders to trastuzumab-based therapy. Building on earlier studies suggesting that HER2+ tumors enriched with molecular and morpho-immunohistochemical features classically ascribed to basal-like tumors are highly aggressive and...
Topics
- Adult
- Aged
- Algorithms
- Breast Neoplasms
- Carcinoma, Ductal, Breast
- Disease-Free Survival
- Drug Resistance, Neoplasm
- Female
- Humans
- Immunophenotyping